Beneficial Ownership Report · SCHEDULE 13G/A
X4 Pharmaceuticals, Inc.
XFORNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- X4 PHARMACEUTICALS INC
- Company CIK
- 0001501697
- Street
- 61 NORTH BEACON STREET
- Street (continued)
- 4TH FLOOR
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02134
Statement details
- Amendment number
- 2
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- FMR LLC
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 4,558,616.00
- Percent of class
- 4.6
- Sole voting power
- 4,558,586.00
- Shared voting power
- 0.00
- Sole dispositive power
- 4,558,616.00
- Shared dispositive power
- 0.00
Reporting person 2
- Name
- Abigail P. Johnson
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 4,558,616.00
- Percent of class
- 4.6
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 4,558,616.00
- Shared dispositive power
- 0.00
Item 1
Issuer
X4 PHARMACEUTICALS INC
Principal executive office address
61 NORTH BEACON STREET,4TH FLOOR,BOSTON,MA,US,02134
Item 2
Citizenship
Not applicable
Filing person
FMR LLC
Principal business or residence address
245 Summer Street, Boston, Massachusetts 02210
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
4.6
Amount beneficially owned
4558616.00
Sole voting power
Please see the responses to Items 5 and 6 on the cover page.
Shared voting power
0.00
Sole dispositive power
4558616.00
Shared dispositive power
0.00
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of X4 PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of X4 PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7
Not applicable indication
N
Subsidiaries
See attached Exhibit 99.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Please see Exhibit 99 for 13d-1(k) (1) agreement.
Signature comments
* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Signature 1
- Reporting person
- FMR LLC
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
- Date
- 10/06/2026
Signature 2
- Reporting person
- Abigail P. Johnson
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
- Date
- 10/06/2026
Filed exhibits
- EX-99 ↗exhibit99.txt
Company context
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 8, 2026
- 4 filingOct 5, 2026
- 144 filingOct 1, 2026
- Other EventsSep 9, 2026
- Other EventsSep 8, 2026